^
Association details:
| Biomarker: | MET mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | c-MET inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features
Published date:
08/07/2020
Excerpt:
Our data strongly suggest that MET represents a major oncogenic driver gene in BSA-PRCC, harboring a higher frequency of MET mutation that encourages to further explore the benefice of anti-MET targeted therapies for aggressive BSA-PRCC.
DOI:
10.1038/s41379-020-0645-6
